August 18, 2026
The D.C. Circuit on Tuesday partially vacated a lower court judgment that had upheld the U.S. Food and Drug Administration's approval of a label without braille for Teva Pharmaceuticals' generic version of a drug often prescribed to blind people.
March 12, 2026
The D.C. Circuit spent more than three hours Thursday going round with Vanda Pharmaceuticals and the U.S. Food and Drug Administration about whether the label for a generic sleep-wake disorder medication is "the same" as the branded one because it doesn't include Braille.
June 13, 2025
Vanda Pharmaceuticals Inc. is urging the D.C. Circuit to reverse a lower court decision upholding the U.S. Food and Drug Administration's approval of a generic sleep-disorder drug without Braille labeling, a move the company argues jeopardizes patient safety.